<DOC>
	<DOC>NCT00468039</DOC>
	<brief_summary>This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.</brief_summary>
	<brief_title>A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male or female (nonfertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry Body mass index 2240 kg/meter squared HbA1c &gt; 11% and/or FPG &gt;270 mg/dL Pregnant or lactating female History of type 1 diabetes Evidence of significant diabetic complications Treatment with insulin or any other oral antidiabetic agent Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metformin</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>initial combination</keyword>
</DOC>